{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:00:12Z","timestamp":1762459212027,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Otsuka"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Millennium"},{"name":"Otsuka"},{"name":"Millennium"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"name":"Otsuka"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.bbmt.2014.08.007","type":"journal-article","created":{"date-parts":[[2014,8,16]],"date-time":"2014-08-16T03:31:18Z","timestamp":1408159878000},"page":"1949-1957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation"],"prefix":"10.1016","volume":"20","author":[{"given":"C\u00e9sar O.","family":"Freytes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Toro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa F.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Voravit","family":"Ratanatharathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6rg\u00fcn","family":"Akpek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Entezam","family":"Sahovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido J.","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell J.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulio E.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louie H.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Elekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunobu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna E.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.08.007_bib1","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1080\/10428190903085936","article-title":"Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma","volume":"50","author":"Burzynski","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.08.007_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bmt.2008.334","article-title":"Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma","volume":"43","author":"Olin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ajh.20641","article-title":"Prolonged overall survival with second on-demand autologous transplant in multiple myeloma","volume":"81","author":"Elice","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2014.08.007_bib5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2011.04.005","article-title":"Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry","volume":"17","author":"Cook","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib7","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1002\/cncr.26662","article-title":"Durable remission with salvage second autotransplants in patients with multiple myeloma","volume":"118","author":"Shah","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.08.007_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.2000.01979.x","article-title":"Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma","volume":"109","author":"Lahuerta","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2014.08.007_bib9","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.08.007_bib10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","article-title":"Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan\u00a0+ cyclophosphamide for allogeneic bone marrow transplantation","volume":"84","author":"Lee","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2014.08.007_bib13","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.bbmt.2012.11.067","article-title":"Pharmacokinetic-directed dose adjustment is essential for intravenous busulfan exposure optimization: findings from a multi-center phase II study of autologous hematopoietic stem cell transplantation for lymphoma in North America","volume":"19","author":"Lill","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","article-title":"Plasma concentration monitoring of busulfan: does it improve clinical outcome?","volume":"39","author":"McCune","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2014.08.007_bib16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2174\/138161208785061382","article-title":"Therapeutic drug monitoring of busulfan in transplantation","volume":"14","author":"Russell","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bbmt.2014.08.007_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/bbmt.2002.v8.abbmt080619","article-title":"A\u00a0limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan","volume":"8","author":"Vaughan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib19","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2014.08.007_bib20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.08.007_bib21","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-10-1662","article-title":"A\u00a0phase I\/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study","volume":"16","author":"Lonial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2014.08.007_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.08.007_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.bmt.1705131","article-title":"Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation","volume":"36","author":"Chang","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbmt.2006.03.016","article-title":"Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen","volume":"12","author":"Aggarwal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib25","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.bbmt.2012.02.006","article-title":"Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation","volume":"18","author":"Zhang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib26","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib27","first-page":"18","article-title":"Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow","year":"1993","journal-title":"Sem Oncol"},{"key":"10.1016\/j.bbmt.2014.08.007_bib28","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","article-title":"Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation","volume":"18","author":"Perkins","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib29","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1177\/0091270009357430","article-title":"Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration","volume":"50","author":"Salinger","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2014.08.007_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbmt.2011.06.013","article-title":"Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients","volume":"18","author":"Yeh","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.08.007_bib31","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2014.08.007_bib32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.08.007_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114005060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114005060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:49:18Z","timestamp":1761058158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114005060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1083879114005060"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.08.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}